Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160601 · ClinicalTrials.gov registry record · Phase 2
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
A Phase 2 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT01160601 is a Phase 2 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT01160601, a Phase 2 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Interventions
- DRUG bavituximab
- DRUG Paclitaxel / Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160601
The ClinicalTrials.gov registry entry for NCT01160601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bavituximab is the first listed.
NCT01160601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01160601 about?
NCT01160601 is a clinical study titled "Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer". This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT01160601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2010-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01160601?
The interventions under investigation include: bavituximab (DRUG), Paclitaxel / Carboplatin (DRUG).
Who is sponsoring clinical trial NCT01160601?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.